Tango Therapeutics, Inc.
TNGX
$18.08
$0.784.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -100.00% | 1,591.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.00% | 1,591.64% | |||
| Cost of Revenue | 4.17% | -6.07% | |||
| Gross Profit | -239.59% | 177.62% | |||
| SG&A Expenses | 9.40% | -21.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.35% | -9.99% | |||
| Operating Income | -397.50% | 134.35% | |||
| Income Before Tax | -344.45% | 140.89% | |||
| Income Tax Expenses | -450.00% | -128.57% | |||
| Earnings from Continuing Operations | -343.95% | 140.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -343.95% | 140.88% | |||
| EBIT | -397.50% | 134.35% | |||
| EBITDA | -382.94% | 136.26% | |||
| EPS Basic | -305.80% | 140.71% | |||
| Normalized Basic EPS | -295.97% | 140.73% | |||
| EPS Diluted | -326.54% | 136.98% | |||
| Normalized Diluted EPS | -308.08% | 138.36% | |||
| Average Basic Shares Outstanding | 18.59% | 0.38% | |||
| Average Diluted Shares Outstanding | 11.72% | 6.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||